Stock Scorer

Assembly Biosciences, Inc. (ASMB)

20.34USD -10.67% (-2.43)

Over 5Y: -48.6%

Style
Area Line Line with markersshows 1Y Steps Candlesshows 6M Hollow candlesshows 6M Barsshows 6M

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

10 20 30 40
2022 2023 2024 2025 2026

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›

Assembly Biosciences, Inc. reported revenue of 13.4M USD for the quarter ending 30 June 2026, up 42.0% from 9.4M a year earlier. Every figure, period by period ›

Q3 '21 — Revenue: 6.3M Q3 '21 — Operating Cash Flow: -18.9M Q3 '21 — Free Cash Flow: -18.9M Q3 '21 — Net Income: -18.8M Q4 '21 — Revenue: 0 Q4 '21 — Operating Cash Flow: -19.4M Q4 '21 — Free Cash Flow: -19.4M Q4 '21 — Net Income: -60.3M Q1 '22 — Operating Cash Flow: -27.5M Q1 '22 — Free Cash Flow: -27.5M Q1 '22 — Net Income: -23.1M Q2 '22 — Operating Cash Flow: -17.9M Q2 '22 — Free Cash Flow: -17.9M Q2 '22 — Net Income: -24.5M Q3 '22 — Operating Cash Flow: -19.8M Q3 '22 — Free Cash Flow: -19.9M Q3 '22 — Net Income: -23.1M Q4 '22 — Operating Cash Flow: -19.3M Q4 '22 — Free Cash Flow: -19.3M Q4 '22 — Net Income: -22.4M Q1 '23 — Revenue: 0 Q1 '23 — Operating Cash Flow: -23.4M Q1 '23 — Free Cash Flow: -23.4M Q1 '23 — Net Income: -18.9M Q2 '23 — Revenue: 0 Q2 '23 — Operating Cash Flow: -13.6M Q2 '23 — Free Cash Flow: -13.7M Q2 '23 — Net Income: -16.9M Q3 '23 — Revenue: 0 Q3 '23 — Operating Cash Flow: -13.8M Q3 '23 — Free Cash Flow: -14M Q3 '23 — Net Income: -14.4M Q4 '23 — Revenue: 7.2M Q4 '23 — Net Income: -11M Q1 '24 — Revenue: 5.8M Q1 '24 — Operating Cash Flow: -18.4M Q1 '24 — Free Cash Flow: -18.4M Q1 '24 — Net Income: -9.1M Q2 '24 — Revenue: 8.5M Q2 '24 — Operating Cash Flow: -17.1M Q2 '24 — Free Cash Flow: -17.1M Q2 '24 — Net Income: -11.2M Q3 '24 — Revenue: 6.8M Q3 '24 — Operating Cash Flow: -15.2M Q3 '24 — Free Cash Flow: -15.2M Q3 '24 — Net Income: -9.6M Q4 '24 — Revenue: 7.4M Q4 '24 — Operating Cash Flow: -407K Q4 '24 — Free Cash Flow: -407K Q4 '24 — Net Income: -10.3M Q1 '25 — Revenue: 9.4M Q1 '25 — Operating Cash Flow: -23.4M Q1 '25 — Free Cash Flow: -23.4M Q1 '25 — Net Income: -8.8M Q2 '25 — Revenue: 9.6M Q2 '25 — Operating Cash Flow: -16.8M Q2 '25 — Free Cash Flow: -16.8M Q2 '25 — Net Income: -10.2M Q3 '25 — Revenue: 10.8M Q3 '25 — Operating Cash Flow: -15.1M Q3 '25 — Free Cash Flow: -15.2M Q3 '25 — Net Income: -9.2M Q4 '25 — Operating Cash Flow: 14.2M Q4 '25 — Free Cash Flow: 14.2M Q4 '25 — Net Income: 22.1M Q1 '26 — Revenue: 8.2M Q1 '26 — Operating Cash Flow: -22.1M Q1 '26 — Free Cash Flow: -22.1M Q1 '26 — Net Income: -9.1M Q2 '26 — Revenue: 13.4M Q2 '26 — Operating Cash Flow: -15.5M Q2 '26 — Free Cash Flow: -15.5M Q2 '26 — Net Income: -3.9M -60M -40M -20M 0 20M 40M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

2.6
DSO 4.1 days
SG&A / sales 27.6%
Profit margin -0.058%
ROA -0.013%
ROE -0.014%
Accruals 11.6%
EBITDA margin -12.0%
FCF margin -53.3%
OCF margin -53.2%
ROCE -2.9%
OE margin -62.6%
Oper. margin -12.2%

16 of 19 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

5.8
P/C 1.3×
EV/Sales 1.4×
P/B 1.4×
FCF yield -9.2%
EV/OE -2.2×

5 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

2.6
RPO / sales 0.23×

4 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

8.7
Cash runway 8.3 yr
Current ratio 45.9×
Debt / Eq 0.0×
Debt payback 0.0 yr
ND/EBITDA 3.3
Quick ratio 14.0×
F-score 3.9 pts

11 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

7.9
Sales CAGR 4Y +84.4%
Sales/sh Y/Y +35.7%
Shares change +86.8%

5 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.

Companies of a similar size

The nearest by market value among the companies read here whose shares are quoted in USD. Size alone: nothing here says they are in the same business.

Every listed company from the United States, largest first ›